11:09 AM EDT, 10/30/2026 (MT Newswires) -- BofA Global Research reiterated AstraZeneca's (AZN.L, AZN.ST) buy rating following the drugmaker's third-quarter financial results amid expectations of a "very busy" pipeline path for 2027. The group reported total revenue of $16.2 billion in the quarter, up 7% year over year and 2% ahead of consensus, the research firm wrote in a Friday note. Core EPS also grew 17% over the period to $2.79, beating market forecasts by 8%. "AZN stock down post eplon/S4 fails & BMY speculation (drives LOE and pipe strength debate). Pipe data needed to rebut and we see AVANZAR positive risk-reward and excited for busy '27E (AVANZAR/CAMBRIA1/Farxiga LCM/oPCSK9/PARPi)," analysts said, viewing the valuation as "attractive". "Overall, we are excited about a very busy 27E with several large PIII readouts," BofA added. "Our conviction calls are sizeable and high-probability PIIIs for CAMBRIA-1 (SERD adjuvant switch) and balci/dapa (Farxiga FDC in HF with CKD), with sauraparib(PARPi, early-stage prostate). We see PIII data offering upside to existing FY30E $80bn sales guide and growth post key LOEs." The stock's price objective stands at 165 pounds sterling.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.